Aytu BioPharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joshua R. Disbrow
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 7900 East Union Avenue, Suite 920 Denver CO United States of America 80237
- IPO Date
- Sep 25, 2008
- CIK
- 0001385818
- Website
- aytubio.com
- Similar Companies
- Business
- Aytu BioPharma, Inc. (NASDAQ: AYTU) operates as a specialty pharmaceutical company focused on commercializing novel therapeutics for complex central nervous system (CNS) conditions, including major depressive disorder (MDD) and attention deficit/hyperactivity disorder (ADHD). The company markets prescription products such as Adzenys XR-ODT and Cotempla XR-ODT, extended-release orally disintegrating tablets for ADHD treatment in patients six years and older; Karbinal ER, an extended-release antihistamine suspension for pediatric allergies; and pediatric multi-vitamins Poly-Vi-Flor and Tri-Vi-Flor addressing fluoride deficiencies. It also offers Natesto, a nasal testosterone formulation for male hypogonadism, and plans to launch EXXUA (gepirone), a first-in-class selective serotonin 5HT1a receptor agonist approved for MDD in adults. Founded in 2015 and headquartered in Denver, Colorado, Aytu BioPharma conducts operations primarily in the United States with out-licensing partnerships internationally, including for ADHD products in markets like Israel and Canada. Recent developments include an exclusive U.S. commercialization agreement for EXXUA in 2025, supported by a patent term extension, a $16.6 million public offering, and an expanded lending facility with Eclipse Business Capital extending to 2029; the company divested its consumer health business and exited in-house manufacturing by mid-2024, suspended R&D pipeline development to prioritize CNS-focused profitability, and achieved consistent adjusted EBITDA of $9-10 million over the past three years with over $30 million in cash as of June 2025.
Company News
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
AWM Investment Company Inc. Invests $1.33 Million in Aytu BioPharma Inc. $AYTU
New Strong Sell Stocks for July 20th
New Strong Sell Stocks for July 16th
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Analysts
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
New Strong Sell Stocks for February 2nd
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026